Track topics on Twitter Track topics that are important to you
CUBICIN® (daptomycin for injection), the only once-a-day agent approved for the treatment of MRSA and MSSA in cSSSI, has been shown to be safe1 and effective2 against most Gram-positive organisms in cSSSI.
Click here to view the progression of an actual case of left-ankle cellulitis successfully treated with CUBICIN therapy.
Rapidly bactericidal in vitro,* CUBICIN is the first cyclic lipopeptide and has a mechanism of action distinct from that of any other antibiotic.
With its once-a-day dosing, 30-minute infusion time, and other conveniences, CUBICIN is an ideal agent for outpatient MRSA/MSSA cSSSI care. (Preparation and Administration instructions.)
Questions about billing and reimbursement? Check out our Billing Guide for Cubicin® online or download the pdf.
Lexington Headquarters65 Hayden Avenue
United States of America
DelveInsight's, Cubicin API Insights, 2017 report provides product and API manufacturers details across the globe along with the location. The report gives the clear idea on the country wise DMF file...
DelveInsight's pharmaceuticals report, Cubicin Drug Insights, 2017 highlights the Drug marketed details and the Global API Manufacturers details across the globe along with the location. The report c...
These highlights do not include all the information needed to use CUBICIN safely and effectively. See full prescribing information for CUBICIN. CUBICIN (daptomycin for injection) for Intravenous Use...
The purpose of the study is to describe the clinical efficacy of CUBICIN therapy in patients with superficial and deep post-surgical Gram-positive wound infections
The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthet...
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the trea...
The purpose of the study is to evaluate the overall burden to the participant (economic, quality of life, patients satisfaction and freedom from side effects) when treating Gram positive i...
CUBICIN® (daptomycin for injection), the only once-a-day agent approved for the treatment of MRSA and MSSA in cSSSI, has been shown to be safe1 and effective2 against most Gram-positive organisms in ...
We have published hundreds of CUBICIN® news stories on BioPortfolio along with dozens of CUBICIN® Clinical Trials and PubMed Articles about CUBICIN® for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CUBICIN® Companies in our database. You can also find out about relevant CUBICIN® Drugs and Medications on this site too.
MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16 account for 96% of MRSA blood...
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...